Extra Pneumococcal Dose Can Save Lives in Care Homes
An additional dose of a pneumococcal vaccine, either 23-valent pneumococcal polysaccharide vaccine (PPV23) or 20-valent pneumococcal conjugate vaccine (PCV20), for new care home residents upon entry could prevent a substantially higher proportion of invasive pneumococcal disease cases and deaths per dose than the single-dose schedule for 65-year-olds, with the PCV20 vaccine demonstrating greater effectiveness over the PPV23 vaccine.
METHODOLOGY:
Researchers in England conducted an observational surveillance study to evaluate the effect of administering an additional dose of a pneumococcal vaccine, either PPV23 or PCV20, at admission to new residents of older care homes, alongside the routine vaccination.
Using national invasive pneumococcal disease surveillance and other data sources, they analysed 121,587 new care home residents (83,271 women and 38,316 men) to estimate the potential number of invasive pneumococcal disease cases and deaths averted over 5 years and calculated the number needed to vaccinate (NNV) to prevent one vaccine-type case and one death.
They compared these results with those of 603,109 individuals (aged 65 years) from the general population who had received a single vaccine dose.
TAKEAWAY:
PPV23 immunisation of all new care home residents would prevent 36% of PPV23-type lifetime cases of invasive pneumococcal disease (NNV, 687) and 48% of deaths (NNV, 1095).
Similarly, PCV20 immunisation would prevent 75% of PCV20-type lifetime cases of invasive pneumococcal disease (NNV, 384) and 80% of deaths (NNV, 774).
An additional dose of both vaccines could prevent five times more cases and 18 times more deaths than the current immunisation policy for adults aged 65 years.
IN PRACTICE:
"Protecting older adults, especially those in aged care facilities, from infectious diseases is necessary to reduce morbidity and mortality. Vaccination, including against pneumococcus, is an effective strategy to promote healthy ageing," the author of a commentary wrote.
SOURCE:
This study was led by Fariyo Abdullahi, MSc, Immunisation and Vaccine Preventable Diseases, UK Health Security Agency, London, England. It was published online on July 01, 2025, in The Lancet Healthy Longevity.
LIMITATIONS:
The national dataset could not identify individuals in temporary or respite care, potentially leading to an undercount of care home residents. This study relied on invasive pneumococcal disease risk estimates from the older study, which may not have reflected current conditions in England. The NNV might be underestimated as frail residents are less likely to receive invasive investigations.
DISCLOSURES:
The Immunisation and Vaccine Preventable Diseases Division provided vaccine manufacturers with postmarketing surveillance reports on pneumococcal and meningococcal infections, with cost recovery charges applied. One author reported performing contract research for pharmaceutical companies on behalf of St George's University of London and the UK Health Security Agency without personal remuneration. The other authors reported having no competing interests.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
39 minutes ago
- Yahoo
£749 handout from DWP if you have any of these 87 muscle or joint problems
Personal Independence Payment (PIP) is a benefit designed for people who require extra help with everyday tasks due to an illness, disability or mental health condition. It is worth up to £749.80 every four weeks and is handed out by the Department for Work and Pensions ( DWP ). PIP is not an out of work benefit, so you may be eligible for PIP if you are working at present, reports MirrorOnline. READ MORE: Nationwide, Barclays and NatWest customers handed £185 to switch with rival bank Get breaking news on BirminghamLive WhatsApp, click the link to join How much you could get in PIP all depends on how your condition your health condition or disability impacts your life. There is no official list of conditions that make you eligible for PIP. As per DWP data, there are more than one million adults who are in receipt of PIP for musculoskeletal conditions, out of the 3.7million who claim PIP overall. Musculoskeletal conditions are injuries and disorders that impact the body's movement or musculoskeletal system such as muscles, tendons, ligaments, nerves, discs and blood vessels. PIP is made up of two components - a daily living rate and a mobility rate - and you can be entitled to both or just one of these. If you are eligible for both the enhanced rate of the daily living allowance and the mobility allowance, you would receive £749.80 a month. Daily Living Standard rate: £73.90 a week Enhanced rate: £110.40 a week Mobility Standard rate: £29.20 a week Enhanced rate: £77.05 a week Osteoarthritis Osteoarthritis of Hip Osteoarthritis of Knee Osteoarthritis of other single joint Primary generalised Osteoarthritis Chronic pain syndrome Chronic fatigue syndrome (CFS) Fibromyalgia Pain syndromes - Chronic - Other / type not known Inflammatory arthritis Ankylosing spondylitis Arthritis - Psoriatic Arthritis - Reactive Inflammatory arthritis - Other / type not known Juvenile chronic arthritis (Still's disease) Rheumatoid arthritis Crystal deposition disorders Crystal deposition disorders - Other / type not known Gout Pseudogout Osteonecrosis and osteochondritis Osteochondritis Osteonecrosis Metabolic and endocrine disorders Osteomalacia Osteoporosis Other metabolic and endocrine disorders of musculoskeletal system Paget's disease Rickets Genetic disorders, dysplasias and malformations Achondroplasia Epiphyseal dysplasia - multiple Genetic disorders, dysplasias and malformations - Other / type not known Hereditary multiple exostosis (diaphyseal aclasis) Hypermobility syndrome Marfan's syndrome Osteogenesis imperfecta Benign tumours of bone Tumours of bone - benign Fracture complications Compartment syndrome (Volkmann's ischaemia) Fracture complications - Other / type not known Sudek's atrophy Other generalised musculoskeletal conditions Generalised musculoskeletal disease - Other / type not known Shoulder disorders Adhesive capsulitis (frozen shoulder) Rotator cuff disorder Shoulder disorders - Other / type not known Shoulder instability Elbow disorders Elbow disorders - Other / type not known Golfers elbow (medial epicondylitis) Tennis elbow (lateral epicondylitis) Wrist and hand disorders Carpal tunnel syndrome Dupuytren's contracture Tendon lesions Tenosynovitis Wrist and hand disorders - Other / type not known Neck disorders Cervical disc lesion Cervical spondylosis Neck disorders - Other / type not known Whiplash injury Non specific back pain Back pain - Non specific (mechanical) Specific back pain Back pain - Specific - Other / type not known Kyphosis Lumbar disc lesion Lumbar spondylosis (OA spine) Schuermann's disease Scoliosis Spinal stenosis Spondylolisthesis Hip disorders Dislocation of the hip - congenital Hip disorders - Other / type not known Perthes disease Slipped upper femoral epiphysis Knee disorders Bursitis Chondromalacia patellae Knee disorders - Other / type not known Ligamentous instability of knee Meniscal lesions Osgood schlatters disease Osteochondritis dissecans Patellar dislocation - Recurrent Ankle and foot disorders Ankle and foot disorders - Other / type not known Club foot (talipes) Fore foot pain (Metatarsalgia) Hallux valgus /rigidus Amputations Amputation - Lower limb(s) Amputation - Upper limb(s) Amputations - Upper & Lower limb/s Injuries/fracture/Dislocation Abdomen - Injuries/Fracture/Dislocation of Lower limb - Injuries/Fracture/Dislocation of Multiple - Injuries/Fracture/Dislocation Pelvis - Injuries/Fracture/Dislocation of Spine - Injuries/Fracture/Dislocation of Thorax - Injury/Fracture/Dislocation of Upper limb - Injury/Fracture/Dislocation of Other regional musculoskeletal disease Musculoskeletal disease - Regional / Localised - Other / type not known
Yahoo
43 minutes ago
- Yahoo
OCD's Origins Might Not Lie in The Brain Like We Thought
Obsessive-compulsive disorder (OCD) affects up to 3 percent of people worldwide and remains one of the most challenging mental health conditions to treat effectively. That makes any fresh insight into OCD's root causes especially valuable – like a new study pointing to a surprising suspect: the bacteria living in our gut. The research from China explored how the gut microbiota – the complex community of bacteria that live in the digestive system – may influence whether a person develops OCD, and identified six types of bacteria that appear to be linked with the condition. A steady stream of studies has shown close connections between the brain and the gut, but this is the first to provide compelling evidence that gut bacteria may actually help cause it. The researchers used genetic data to strengthen the case for causation. Related: "Previous studies have indicated a potential link between the gut microbiota and OCD," write the researchers from Chongqing Medical University in their published paper. "However, the exact causal relationship remains uncertain." "Our analysis suggested that specific gut microbiota might have a causal relationship with OCD, revealing potential intervention strategies for the prevention and treatment of this disorder." To explore this link, the researchers used a genetic approach known as Mendelian randomization, which allows scientists to infer causality by analyzing genetic variants that influence both OCD and gut bacteria. They assessed links between genetic data and gut bacteria in a sample of 18,340 people, and the links between genetic data and OCD in a separate sample of 199,169 people. Although these were two discrete sets of data, the study used Mendelian randomization to essentially bridge the gap and connect gut bacteria patterns with OCD. Because our genes are fixed at birth and not shaped by environment or lifestyle, this method helps strengthen the case that gut bacteria might directly contribute to OCD, rather than just being an effect of it. However, more data and more controlled experiments will be needed to confirm a causal link. Three types of bacteria appeared to be protective against OCD: Proteobacteria, Ruminococcaceae, and Bilophila. Another three seemed to increase the risk of OCD: Bacillales, Eubacterium, and Lachnospiraceae UCG001. Interestingly, many of these bacteria have been linked with the brain before. For example, previous studies have found a connection between low levels of Ruminococcaceae species and depression. These findings expand what we already know about the gut-brain axis and how one can affect the other. "Future research should employ longitudinal designs and diverse populations to validate and expand upon these findings, as well as a more in-depth classification of microbes and their metabolic products, to further understand the role of gut microbiota in OCD," write the researchers. Down the line – and it's still a way off – we may have a new way to treat or prevent OCD, by controlling gut bacteria mixtures. For people living with the condition – and the families, friends, and clinicians who support them – this could eventually offer new hope. "Despite the utilization of cognitive behavioral therapy and selective serotonin reuptake inhibitors in OCD treatment, a notable 25–40 percent of patients experience suboptimal or no response to these interventions," write the researchers. "Moreover, the personal and societal toll of OCD is substantial." The research has been published in the Journal of Affective Disorders. The News Cycle Is a Stress Monster. But There's a Healthy Way to Stay Informed. Surprise Discovery About Sugar in The Brain Could Help Fight Alzheimer's Air Pollution 'Strongly Associated' With DNA Mutations Tied to Lung Cancer
Fast Company
3 hours ago
- Fast Company
AI could be science's strongest ally
Across the U.S. and parts of Europe, science funding is in crisis. In the U.S., a planned $18 billion worth of cuts to federal research have already halted trials, triggered mass layoffs, and shut down entire programs. Europe isn't immune either, with Horizon, Europe's flagship funding program for research and innovation, also facing rollbacks. These cuts are stretching researchers thin and slowing down innovation when we need it most. Breakthroughs in cancer, rare diseases, and drug development require time, space, and the freedom to explore. Instead, scientists are burning out and many are even walking away, with a recent Nature survey showing that 75% of U.S.-based researchers are considering relocation. With China ramping up investment in AI, the U.S. and Europe risk falling behind just as science enters its most exciting era. Agentic AI could ease the burden Scientific research is slow and expensive, not because of a lack of ideas, but because the tools haven't kept up. Knowledge is buried in siloed papers, scattered datasets, and disconnected systems, and pulling it all together takes time, money, and a lot of manual effort, slowing down even the most promising discoveries. This is where AI comes in as a true lab partner. Unlike the AI systems most of us are familiar with, agentic AI can plan and carry out tasks, all from a single prompt. Scientists can access a suite of agents that will handle the repetitive work that eats up their time, like writing reports, reviewing literature, or designing and running early-stage experiments in the lab. Tech companies and academic researchers are already starting to develop agentic AI to help achieve this. Owkin's K Navigator, Google's AI co-scientist, and Stanford's Biomni reflect a growing shift towards the adoption of agentic co-pilots that let scientists engage with their data as naturally as they would with a colleague. K Navigator is already showing that it can boost productivity by up to 20 times, giving researchers the freedom to focus on making breakthroughs. K Navigator exclusively accesses and analyses spatial multiomic data from MOSAIC Window, a subset of the largest spatial omics dataset in oncology. This allows researchers to better understand how different cells work together in the tumor micro-environment and advance vital cancer research. Agentic AI can help researchers shape hypotheses, work with complex data, and uncover insights, without needing a data science team to guide every step. This kind of acceleration will not only help researchers meet deadlines, but also open up scientific questions that might otherwise go unexplored. We hear this need from researchers every day. Many feel compelled to maintain the same high standards and deliver more data, more trials, and more publications, with fewer resources. In cancer centers and university labs alike, time is the scarcest resource. Agentic AI, embedded into real workflows, can effectively remove some of the friction that slows science down. More time on what matters AI agents won't replace critical thinking or peer review. But with the right safeguards and design (e.g. accurate source referencing and intuitive data visualization), they can help scientists spend less time on admin and more time on what really matters to advance treatments and diagnostics for patients. Because if we can't increase budgets, we need to increase impact. That means giving scientists the tools to do more with less, without burning them out or holding them back. Now is the moment to get this right, otherwise, the cost of underfunding science won't just be slower progress. It'll be lost cures, missed breakthroughs, and a generation of researchers who walk away.
